445 related articles for article (PubMed ID: 16893422)
1. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
Poirier S; Prat A; Marcinkiewicz E; Paquin J; Chitramuthu BP; Baranowski D; Cadieux B; Bennett HP; Seidah NG
J Neurochem; 2006 Aug; 98(3):838-50. PubMed ID: 16893422
[TBL] [Abstract][Full Text] [Related]
2. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Dubuc G; Chamberland A; Wassef H; Davignon J; Seidah NG; Bernier L; Prat A
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1454-9. PubMed ID: 15178557
[TBL] [Abstract][Full Text] [Related]
3. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
5. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
[TBL] [Abstract][Full Text] [Related]
6. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.
Seidah NG; Benjannet S; Wickham L; Marcinkiewicz J; Jasmin SB; Stifani S; Basak A; Prat A; Chretien M
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):928-33. PubMed ID: 12552133
[TBL] [Abstract][Full Text] [Related]
7. The proprotein convertases are potential targets in the treatment of dyslipidemia.
Seidah NG; Prat A
J Mol Med (Berl); 2007 Jul; 85(7):685-96. PubMed ID: 17351764
[TBL] [Abstract][Full Text] [Related]
8. The proprotein convertases and their implication in sterol and/or lipid metabolism.
Seidah NG; Khatib AM; Prat A
Biol Chem; 2006 Jul; 387(7):871-7. PubMed ID: 16913836
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
Maxwell KN; Fisher EA; Breslow JL
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2069-74. PubMed ID: 15677715
[TBL] [Abstract][Full Text] [Related]
10. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Kourimate S; Le May C; Langhi C; Jarnoux AL; Ouguerram K; Zaïr Y; Nguyen P; Krempf M; Cariou B; Costet P
J Biol Chem; 2008 Apr; 283(15):9666-73. PubMed ID: 18245819
[TBL] [Abstract][Full Text] [Related]
11. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
[TBL] [Abstract][Full Text] [Related]
12. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
[TBL] [Abstract][Full Text] [Related]
13. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Abifadel M; Varret M; Rabès JP; Allard D; Ouguerram K; Devillers M; Cruaud C; Benjannet S; Wickham L; Erlich D; Derré A; Villéger L; Farnier M; Beucler I; Bruckert E; Chambaz J; Chanu B; Lecerf JM; Luc G; Moulin P; Weissenbach J; Prat A; Krempf M; Junien C; Seidah NG; Boileau C
Nat Genet; 2003 Jun; 34(2):154-6. PubMed ID: 12730697
[TBL] [Abstract][Full Text] [Related]
14. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.
Benjannet S; Rhainds D; Essalmani R; Mayne J; Wickham L; Jin W; Asselin MC; Hamelin J; Varret M; Allard D; Trillard M; Abifadel M; Tebon A; Attie AD; Rader DJ; Boileau C; Brissette L; Chrétien M; Prat A; Seidah NG
J Biol Chem; 2004 Nov; 279(47):48865-75. PubMed ID: 15358785
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells.
Leblond F; Seidah NG; Précourt LP; Delvin E; Dominguez M; Levy E
Am J Physiol Gastrointest Liver Physiol; 2009 Apr; 296(4):G805-15. PubMed ID: 19179626
[TBL] [Abstract][Full Text] [Related]
16. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
Maxwell KN; Breslow JL
Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
[TBL] [Abstract][Full Text] [Related]
18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.
Lan H; Pang L; Smith MM; Levitan D; Ding W; Liu L; Shan L; Shah VV; Laverty M; Arreaza G; Zhang Q; Murgolo NJ; Hernandez M; Greene JR; Gustafson EL; Bayne ML; Davis HR; Hedrick JA
J Cell Physiol; 2010 Jul; 224(1):273-81. PubMed ID: 20333646
[TBL] [Abstract][Full Text] [Related]
19. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis.
Mousavi SA; Berge KE; Leren TP
J Intern Med; 2009 Dec; 266(6):507-19. PubMed ID: 19930098
[TBL] [Abstract][Full Text] [Related]
20. MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells.
Wang X; Berry E; Hernandez-Anzaldo S; Sun D; Adijiang A; Li L; Zhang D; Fernandez-Patron C
FEBS Lett; 2015 Feb; 589(4):490-6. PubMed ID: 25613181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
